INEX Innovate Unveils Breakthrough Technology for Early Endometrial Cancer Detection

Singapore-based INEX Innovate, a trailblazing group specializing in Women’s Life Science Health Innovations, has introduced epiHERA®, an advanced technology for the early detection of endometrial cancer. This groundbreaking technology was launched during the 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG) held from August 25th to 27th.

Related article: FDA Approves GSK’s PD-1 Medicine for Early-Detected Endometrial Cancer

Addressing a Critical Need 

Approximately one in ten women experiences abnormal bleeding in their lifetime, often necessitating invasive specialist biopsies to rule out endometrial cancer. INEX Innovate’s epiHERA® offers a potential solution, allowing clinicians to employ the widely accepted PAP smear or HPV sampling procedures for early detection. This innovation, developed in collaboration with JH CisPoly, fills a crucial diagnostic gap and promotes equitable access to testing, significantly reducing turnaround time from weeks to days. Validation studies, conducted in partnership with the Chinese University of Hong Kong (CUHK), have shown promising results.

How epiHERA® Works 

epiHERA® leverages advanced PCR testing to identify epigenetic alterations in genes associated with endometrial cancer. The process begins with a simple cervical swab, similar to cervical cancer screening, followed by genomic DNA extraction and bisulfite conversion. The test concludes with real-time PCR analysis targeting hypermethylated CDO1 and CELF4 genes, providing results within approximately six hours.

INEX Innovate’s Vision

Kane Black, CEO of INEX Innovate, described the launch of epiHERA® as a “game-changer” in endometrial cancer detection, showcasing the company’s commitment to timely interventions and improved patient outcomes. epiHERA® is the latest addition to their expanding portfolio, further solidifying their position as Asia’s leading women’s life science platform. The company’s dedication to empowering women and healthcare professionals with innovative tools demonstrates its ongoing commitment to transforming women’s health. Researchers can now access epiHERA® for validation within their population cohorts, fostering diverse applications and a comprehensive understanding of its effectiveness.

INEX Innovate, with a strong commercial portfolio and numerous patents, is uniquely poised to address unmet needs in fetal health and women’s oncology. Through its subsidiary, iGene Laboratory Pte Ltd, INEX operates a cutting-edge Next Generation Sequencing Laboratory, providing diagnostic testing, clinical research, and infectious testing services.

Author

Sinead Huang